Letters to the Editor between esophageal adenocarcinoma (EAC) and gastric cancer (GC) incidence rates in 33 local cancer registries within Italy. Th ey applied the same methodology we used in the cross-sectional part of our recent international study involving 51 countries ( 2 ) for analyzing the correlation between the two cancers. Th e authors found non-signifi cant correlations between EAC and either Non-cardia gastric cancer (NCGC) or total gastric cancer (TGC) within the Italian population.
In the cross-sectional part of our international study, we had a group of countries, including Italy, with a low incidence of both TGC and EAC, which we called group C in Figure 1 . Th is group of countries did not contribute to the inverse correlation between the two cancers seen in our cross-sectional study.
Th e Italian national incidence of 0.61 for EAC in men estimated in our study (which is calculated by pooling the data from regis tries meeting a minimum quality standard) is in the middle of the range (0.3-1.6) reported by the Italian investigators. Even the highest rates within these ranges (0.3-1.6 in men and 0-0.2 in women) for Italy are relatively low by international standards. If we had confi ned our analysis to countries where the rates of EAC were less than 1.6 (for men) or 0.2 (for women), we would also not have observed signifi cant correlations with GC. What drives our observations are the high rates of EAC (exceeding the highest rates seen in Italy) that are associated with low rates of GC. Indeed, in our Figure 1c , it is groups A and B that give rise to the correlation. Th e Italian situation is similar to only having populations in groups C and D, where there is no correlation.
Interestingly, when looking at the longitudinal part of our study (original Table 3 ), data from two Italian registries (Romagna and Torino) showed no correlations between TGC and EAC. Th is again confi rms the fact that these populations did not contribute to the overall worldwide inverse correlations between two cancers.
We have discussed possible explanations for these observations in our paper, including environmental factors, lifestyle factors, and cancer registration quality. acted opposite eff ects on esophageal and gastric cancers did not appear.
Th is does not mean that this process would not be on going, but just that its possible eff ects are not evident yet. Such results would be consistent with an opposite eff ect on the two organs of a common environmental factor, e.g., the decreasing prevalence of Helicobacter pylori infection ( 2 ).
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In the paper, based on population-based cancer registries from Cancer Incidence in Five Continents X ( 3 ), Italy contributed to the correlation computations only with the average pool of its data.
To
According to Derakhshan we computed the age-adjusted incidence rates (world standard) for esophageal adenocarcinoma (EAC) for gastric cancer (GC) and for the proportions of non-cardia (NCGC, CC16.1-6) gastric cancers out of all gastric cancers with a known topography (C16.1-6). For evaluating the correlation between EAC and overall GC and between EAC and NCGC we computed Spearman's rho correlations, overall and by sex.
In Italy there was certain heterogeneity in GC incidence which ranged from 8.4 cases/100,000/year to 21.7 among men and from 4.1 to 11.1 among women. As regards NCGC rates ranged from 6.8 to 19.8 for men and from 3.8 to 10.7 among women. Finally, EAC varied from 0.3 to 1.6 for men and from 0 to 0.2 for women.
In the present analysis the EAC incidence rates showed a non-signifi cant positive correlation either with NCGC (Spearman rho's correlation=+0.12, P =0.51 for men and rho=+0.16, P =0.37 for women) and with GC (rho=+0.12, P =0.51 men and rho=+0.14, P =0.42, women).
According to our results, although in Italy, there is a consistent variability in gastric and esophageal cancers incidence, we did not fi nd out any clue for negative correlations between EAC and NCGC, and EAC and GC.
Th erefore, in this study which represents a full picture of Italy involving the information for all the 33 available regional cancer registries, the role of a common environmental factor which may have
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We have begun an investigation of the eff ects of vonoprazan on patients with EoE who were found to be resistant to initial PPI (esomeprazole) therapy over 3 months at a standard dose (20 mg). At this time, four patients with EoE are treated ( Table 1 ) . Each is a middle-aged male and aff ected by concurrent allergic disease. All were treated by vonoprazan at a standard dose (20 mg) for at least 2 months and reevaluated for its effi cacy by use of eso phageal biopsy fi ndings, which showed that 3 of 4 had a positive response to vonoprazan treatment, with both symptoms and eosino philic infi ltration disappearing during the 2-month administration period. In the remaining patient (case 4), clinical symptoms clearly improved, but endoscopic fi ndings did not change aft er 2 months on vonoprazan without any adverse events. Moreover, there was a marked increase in eosinophils (210/HPF). Th en, he was switched to topical steroid treatment and confi rmed histological remission. Further research is ongoing to clarify the clinicopathological features of patients with P-CAB-responsive EoE.
PPI may have anti-infl ammatory eff ects beyond gastric acid suppression ( 6 ), whereas those eff ects of P-CAB administration remain unclear. Although our study was limited by evaluating PPI responsiveness with a standard dose, our data indicate that adequate and sustained acid suppression by a P-CAB is an attractive treatment candidate and may improve cure rates in patients with suspected EoE, especially who are CYP2C19 rapid metabolizers.
To the Editor:
We read with great interest the article by Molina-Infante et al.
( 1 ) describing an important current issue regarding long-term effi cacy of proton pump inhibitor (PPI) therapy in patients with PPI-responsive esophageal eosinophilia (PPI-REE). Th ere, the authors demon strated that a CYP2C19 rapid metabolizer genotype and rhinoconjunctivitis were independent predictors of loss of response to PPI, but patients frequently responded to PPI dose escalation.
A recent systematic review demonstrated that approximately half of the investigated patients with symptomatic esophageal eosinophilia suggestive of eosinophilic eso phagitis (EoE)-achieved histological remission with PPI therapy ( 2 ) . Plasma PPI level is aff ected by CYP2C19 genotype, and lower effi cacy of PPI therapy has been shown in patients with rapid metabolizer genotype. However, the infl uence of CYP2C19 genotype on the effi cacy of PPI therapy for PPI-REE patients has not been evaluated. Results of the authors' study are promising and provided a new question: Is stronger acid suppression more eff ective for PPI-REE patients?
Vonoprazan is a novel potassiumcompetitive acid blocker (P-CAB) recently approved in Japan that has shown more potent and sustained suppression of gastric acid secretion as compared with PPIs ( 3 ). Moreover, the pharmacokinetics of vonoprazan are not sensitive to CYP2C19 polymorphism ( 4 ). Given its stronger acid-suppressive eff ect in comparison with PPIs ( 5 ), this P-CAB can be more eff ective for esophageal eosinophilia. However, the eff ect of vonoprazan on EoE remains to be reported.
